A Phase 1 Study of SHR-A1811 in Patients With Selected HER2 Expressing Tumors
Ontology highlight
ABSTRACT: This is a single arm, open-label, dose escalation, PK expansion and efficacy expansion study of phase I. The purpose of this study is to assess the tolerability, safety, pharmacokinetics and immunogenicity of SHR-A1811 and preliminary anti-tumor efficacy in HER2-expressing advanced gastric or gastroesophageal junction adenocarcinoma and colorectal cancer.
DISEASE(S): Gastric Cancer,Colorectal Cancer,Colorectal Neoplasms
PROVIDER: 2348822 | ecrin-mdr-crc |
REPOSITORIES: ECRIN MDR
ACCESS DATA